COMPANY ANNOUNCEMENT
StemMedical A/S today announced that the Human Tissue Authority (HTA) has approved the use of Stemform® within the United Kingdom (UK). Stemform® is a cell-based natural filler used for implant-free breast augmentation (Stemform® BA) or volume replacement after artificial breast implant removal (Stemform® AIR).
“We are pleased with the HTA approval for Stemform® in the UK which supports our ambition to improve lives of women by offering innovative FemHealth solutions”, said Klaus Langhoff-Roos, chief executive officer at StemMedical. “The FemHealth space suffers from lack of research and innovation, and the continued use of artificial implants and synthetic fillers after half a century on the market, despite all the known downsides, reflects this. With Stemform® we raise the bar with a natural, safe and evidence-based alternative to artificial implants”.
“Many of our patients are searching for alternatives to traditional breast augmentations with implants” explains Dr. Aris Sterodimas, plastic surgeon, and Head of Plastic & Reconstructive Surgery Department at Metropolitan General Hospital, in Athens, Greece. “Stemform® offers a unique alternative for our female patients wanting a natural implant-free breast augmentation or have a desire to get their breast implants removed but keep the breast volume”.
About Stemform®:
Stemform® is an approved cell-based natural filler product consisting of ex-vivo expanded autologous MSC(AT)s. Stemform® is reconstituted with freshly harvested autologous fat before it’s applied through a fat grafting procedure of the breast. Stemform® is currently available for breast augmentation (Stemform® BA) or following artificial implant removal (Stemform® AIR)
Site: www.stemform.com
Instagram: www.instagram.com/stemform/
About StemMedical®:
StemMedical A/S is a private Denmark-based cell therapy biotech dedicated to drive change to create a new paradigm for stem cell regenerative therapies. StemMedical is meeting this ambition through its two focus areas lines: FemHealth and Therapeutics. In FemHealth we focus on plastic and reconstructive surgery, and our product Stemform® is commercially launched in Denmark. In Therapeutics, we are initially focusing on osteoarthritis of the knee through our Stem-OA pipeline asset.
Site: www.stemmedical.com
LinkedIn: https://www.linkedin.com/company/stemmedical/mycompany/
Further information:
Media: Marc Fauerby Lange (Chief Commercial Officer), marc@stemmedical.com
Investors: Josef Christensen (Chief Business Development Officer), josef@stemmedical.com
Det københavnske stamcellefirma Stemmedical har sikret sig halvdelen af pengene fra en kapitalrejsning, som blev skudt i gang i sommeren sidste år, og som samlet skal indbringe selskabet 112 mio. kr.
Stamcellefirmaet Stemmedical indledte i sommeren 2022 en pengerunde, der skulle sikre selskabet i alt 15 mio. euro, svarende til næsten 112 mio. kr., og nu er halvdelen af pengene i hus, oplyser Stemmedical til Børsen.
Stem Medical vil erstatte brystimplantater med en stamcellebaseret løsning – nye investorer skal sikre europæisk udrulning
Stem Medical tilbyder kosmetiske brystforøgelser med ens egne fedtstamceller og regner med, at det på sigt vil erstatte implantater. Foto: Esther Kofoed Sørensen Foto: Esther Kofoed Sørensen
Markedet for brystoperationer er gigantisk, og danske Stem Medical ser høj vækst forude, hvis virksomheden bare kan snuppe en enkelt procent af markedet.
StemMedical, a Danish developer of a stem cell therapy platform for aesthetic and reconstructive surgery, is in the process of raising a Series B of EUR 15m–EUR 18m, CEO Klaus Langhoff-Roos said.